Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Expects No Change In Naloxone Access Barrier If Prices High For Potential OTC Products

Aug 30 2022

• By Malcolm Spicer

• Source: Shutterstock

Related Content

HRT Reports 'Remarkable Achievement' In OTC Naloxone Phase 1 Clinical Trial Results

Mar 01 2022

Drivers For Allowing OTC Naloxone In US Include Social Justice As Well As Public Health Need

Mar 31 2022

OTC Naloxone NDA In US Gets Fast Track Status

Aug 11 2022

Expanding Naloxone Access Needs Normalizing First-Aid Use, Keeping Purchase Records Private

Apr 04 2022

FDA Has Model Drug Facts Labels For OTC Naloxone, Wants Switch Proposals

Jan 18 2019

Additional Topics

International United States Prescription To OTC Switch FDA Ingredients Advertising, Marketing & Sales Business Strategies Commercial Companies Compliance Consumer Drug Approval Standards Drug Delivery Technology Drug Review Drug Safety Manufacturing OTC Drugs Policy Regulation Reimbursement Review Pathway Safety

More from Rx-to-OTC Switch

More from Health

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window